16 unknown, 15 completed, 12 terminated, 7 recruiting. 26 Phase 2, 16 Phase 1, 10 Not applicable, 5 Phase 3, 2 Early Phase 1.
Follow Nonsmall Cell Lung Cancer: new trials by email Literature Review of Nonsmall Cell Lung Cancer trials Research Report on Nonsmall Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors VMD-102 - Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma | Phase 1 / Phase 2 | Recruiting | VM Discovery, Inc. | 111 | 2026-07-16 | 2026-08-19 |
| XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation XP-102, Trametinib - Cancer, BRAF V600 Mutation | Phase 1 / Phase 2 | Not yet recruiting | Xynomic Pharmaceuticals, Inc. | 221 | 2025-12-31 | 2025-04-10 |
| Evaluating the Efficacy and Safety of AI Localization Models in Multidisciplinary Team Care for NSCLC Treat Regimen - Nonsmall Cell Lung Cancer | Not applicable | Recruiting | Wen-zhao ZHONG | 300 | 2025-12-01 | 2026-06-04 |
| Patient-centered, Optimal Integration of Survivorship and Palliative Care POISE - Stage IV Non-small Cell Lung Cancer, Targeted Therapy | Not applicable | Recruiting | Massachusetts General Hospital | 70 | 2023-09-29 | 2025-11-24 |
| A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer HS-10365 capsules - Nonsmall Cell Lung Cancer | Phase 2 | Recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 62 | 2023-09-25 | 2023-11-27 |
| Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC Genomically Guided Radiation Therapy (RT) - Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer, Stage II | Early Phase 1 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 3 | 2023-05-25 | 2026-04-01 |
| Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors ²¹²Pb-DOTAM-GRPR1 - Cervical Cancer, Breast Cancer | Phase 1 | Recruiting | Orano Med Theranostics, SAS | 48 | 2022-12-22 | 2026-06-11 |
| Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment Durvalumab, Tremelimumab - Nonsmall Cell Lung Cancer | Phase 2 | Withdrawn | Catherine Shu | 2022-12-01 | 2023-06-06 | |
| Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS 1.0% IP-001 for Injection - Metastatic Solid Tumor, Colon Cancer | Phase 1 / Phase 2 | Active not recruiting | Immunophotonics, Inc. | 42 | 2022-11-29 | 2025-01-08 |
| Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation JDQ443, trametinib, Ribociclib - KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 74 | 2022-10-24 | 2026-10-21 |
| A Study of [14C]GB491 in Male Healthy Subjects [14C]GB491 - Breast Cancer, Nonsmall Cell Lung Cancer | Phase 1 | Completed | Genor Biopharma Co., Ltd. | 6 | 2022-09-14 | 2023-05-16 |
| A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors HMBD-002, Pembrolizumab - Cancer, Tumor, Solid | Phase 1 | Completed | Hummingbird Bioscience | 48 | 2022-02-28 | 2025-10-16 |
| Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Immunotherapy - Immune Checkpoint Inhibitors, Metastatic Solid Tumor | Active not recruiting | University of Oklahoma | 72 | 2022-01-31 | 2026-09-18 | |
| NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC efineptakin alfa, Atezolizumab - Carcinoma, Non-Small-Cell Lung, Non-Small Cell Lung Cancer | Phase 2 | Terminated | NeoImmuneTech | 33 | 2021-11-15 | 2026-06-11 |
| Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc - Nonsmall Cell Lung Cancer, Performance Status | Phase 2 | Recruiting | Wake Forest University Health Sciences | 105 | 2020-07-01 | 2026-09-25 |
| First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b XMT-1592 - Ovarian Cancer, Nonsmall Cell Lung Cancer | Phase 1 | Terminated | Mersana Therapeutics | 31 | 2020-05-11 | 2024-03-15 |
| Metabolic and Microbial Profiling of Lung Cancer Breath Collection, Saliva Collection, Blood Collection - Nonsmall Cell Lung Cancer, Nonsmall Cell Lung Cancer Stage | Not applicable | Terminated | Wake Forest University Health Sciences | 1 | 2019-10-11 | 2021-11-05 |
| Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC Anlotinib - Nonsmall Cell Lung Cancer | Not applicable | Unknown | The First Affiliated Hospital with Nanjing Medical University | 83 | 2019-06-15 | 2019-10-22 |
| Study of Lorlatinib in ROS1 Rearranged NSCLC Lorlatinib - Nonsmall Cell Lung Cancer | Phase 2 | Unknown | National Cancer Center, Korea | 35 | 2019-05-02 | 2022-04-06 |
| X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases X-396(Ensartinib) Capsule - Nonsmall Cell Lung Cancer, Brain Metastases | Phase 2 | Active not recruiting | Fudan University | 27 | 2019-04-12 | 2025-07-23 |
Showing 20 of 59. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (59) · Lung Neoplasms (6) · Colorectal Neoplasms (5) · Neoplasm Metastasis (5) · Breast Neoplasms (3) · Melanoma (3) · Neoplasms (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Colonic Neoplasms (2) · Kidney Neoplasms (2) · Ovarian Neoplasms (2) · Recurrence (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1)
Bronchial Neoplasms (59) · Carcinoma, Bronchogenic (59) · Lung Diseases (59) · Neoplasms by Site (59) · Respiratory Tract Diseases (59) · Respiratory Tract Neoplasms (59) · Thoracic Neoplasms (59) · Neoplasms (56) · Lung Neoplasms (53) · Neoplasms by Histologic Type (8) · Digestive System Diseases (7) · Digestive System Neoplasms (7) · Gastrointestinal Diseases (7) · Skin Diseases (7) · Skin and Connective Tissue Diseases (7)
Pemetrexed (5) · Carboplatin (4) · Cisplatin (4) · Docetaxel (4) · Gemcitabine (3) · Nivolumab (3) · Paclitaxel (3) · Radiotherapy (3) · atezolizumab (3) · osimertinib (3) · pembrolizumab (3) · Blood Specimen Collection (2) · Erlotinib Hydrochloride (2) · Gefitinib (2) · Radiotherapy, Intensity-Modulated (2)
Washington University School of Medicine (9) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (2) · Samsung Medical Center (2) · Wake Forest University Health Sciences (2) · AIO-Studien-gGmbH (1) · Alliance Foundation Trials, LLC. (1) · Berry Genomics Co., Ltd. (1) · Bocconi University (1) · Bristol-Myers Squibb (1) · British Columbia Cancer Agency (1) · Catherine Shu (1) · Chul Kim (1) · Dizal Pharmaceuticals (1) · Fox Chase Cancer Center (1) · Fudan University (1)
United States (26) · China (15) · France (5) · Germany (5) · South Korea (5) · Spain (4) · Australia (3) · Belgium (3) · Hungary (3) · Italy (3) · Bulgaria (2) · Canada (2) · Czechia (2) · Greece (2) · Netherlands (2)
Daniel Morgensztern, M.D. (3) · Ramaswamy Govindan, M.D. (3) · Saiama Waqar, M.D. (2) · Abdul Naqash, MD (1) · Aly Karsan, MD (1) · Andrew Bishop, PhD (1) · Caicun Zhou, MD, PHD (1) · Catherine Shu, MD (1) · Cliff Robinson, M.D. (1) · David L Saltman, MD PhD (1) · Diane Beatty, PhD (1) · Donghoon Choi, PhD (1)
PMID 24553385, PMID 25538174, PMID 26643552, PMID 27384348, PMID 28445469, PMID 28899864, PMID 29767677, PMID 30772862, PMID 31703637, PMID 32533785, PMID 32817079, PMID 32916310, PMID 33581821, PMID 34568058, PMID 34631535, PMID 36308296, PMID 36761980, PMID 37591293, PMID 37657460, PMID 38753757, PMID 38968520, PMID 38983151, PMID 40118215, PMID 40199559, PMID 40586961, PMID 40683994, PMID 40702361, PMID 40991883, PMID 41296331, PMID 41808570
2016 (2), P30CA012197 (2), 2015 (1), 2023 (1), K08CA263549 (1), P01CA217797 (1), P30CA086862 (1), U01CA140206 (1)